Infinity Pharmaceuticals Overview
Infinity Pharmaceuticals (INFI) has a ROE of 108.35%, above the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow108.35%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for INFI is 108.35%. That is above the Healthcare sector average of 21.28%. Investors often review this figure alongside Infinity Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, INFI currently prints 108.35% for ROE, while the sector average sits near 21.28%. That is roughly 409.2% above the sector mean. Large gaps often invite a closer look at Infinity Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively Infinity Pharmaceuticals converts resources into returns. At 108.35%, INFI may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting INFI's ROE (108.35%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Infinity Pharmaceuticals's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
